{"filing":{"accession_number":"0001628280-26-042365","cik":"0001662579","ticker":"CCCC","company_name":"C4 Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"cccc-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/cccc-20260611.htm"},"events":[{"id":5491,"run_id":4813,"accession_number":"0001628280-26-042365","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. This clinical trial progress is material to the company's pipeline prospects and would affect a reasonable investor's assessment of the registrant's development stage and competitive position.","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6078,"accession_number":"0001628280-26-042365","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a routine Regulation FD disclosure of a corporate presentation posted to the investor relations website. The filing explicitly disclaims materiality (\"shall not be deemed an admission as to the materiality of any such information\") and is a standard administrative disclosure of investor presentation materials, not a substantive business event like earnings, M\u0026A, executive changes, or financial restatements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:06:08.618725+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6079,"accession_number":"0001628280-26-042365","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. While clinical trial progress is material to a biotech company's valuation and investor assessment, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, impairment, or other defined event type). The disclosure of favorable Phase 1 data would affect a reasonable investor's assessment of the registrant's pipeline prospects and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:06:08.618725+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6078,"accession_number":"0001628280-26-042365","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a routine Regulation FD disclosure of a corporate presentation posted to the investor relations website. The filing explicitly disclaims materiality (\"shall not be deemed an admission as to the materiality of any such information\") and is a standard administrative disclosure of investor presentation materials, not a substantive business event like earnings, M\u0026A, executive changes, or financial restatements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:06:08.618725+00:00","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-06-11"},{"id":6079,"accession_number":"0001628280-26-042365","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"C4 Therapeutics disclosed positive Phase 1 trial data for cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma, presented via a poster at EHA 2026 Congress and accompanied by a press release. While clinical trial progress is material to a biotech company's valuation and investor assessment, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, M\u0026A activity, impairment, or other defined event type). The disclosure of favorable Phase 1 data would affect a reasonable investor's assessment of the registrant's pipeline prospects and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T11:06:08.618725+00:00","company_name":"C4 Therapeutics, Inc.","ticker":"CCCC","filing_date":"2026-06-11"}]}